HealthMore in Health→
FDA Approves J&J's Icotyde, a New Psoriasis Pill With $5B+ Potential
The FDA has approved Johnson and Johnson's icotrokinra, branded Icotyde, for moderate-to-severe psoriasis in patients aged 12 and up — a drug the company expects to become a multi-billion dollar blockbuster.
Key Takeaways
- FDA approved J&J's icotrokinra (Icotyde) for moderate-to-severe plaque psoriasis in patients aged 12 and older
- Icotyde is an oral small molecule inhibitor, offering a pill alternative to existing injectable biologic treatments
DE
DT Editorial Team··3 min read·via endpoints.news